FinancingBioLamina AB bags €19m funding for expansionFrench-US-based investment specialist Lauxera Capital Partners announced today that it has invested €17m in Swedish cell culture company BioLamina AB (BioLamina) more ➔
radiopharmaceuticalRadiotherapy R&D partnershipOrano Med SAS and Orbit Discovery Ltd announced a collaboration to develop Peptide Receptor Radionuclide Therapies for cancer cells and develop novel radiopharmaceuticals. more ➔
Tech transferBioInnovation Institute Boosts Six Life Science CompaniesNon-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial … more ➔
NGTMajority of EU agri-council supports NGT deregulationAt a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July. more ➔
New detection method for protein degraders German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell. more ➔
ScienceStudy: New breeding methods hardly contribute to climate protectionAccording to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050. more ➔
vaccinesCEPI commits up to US$80m to University of Oxford to develop vaccinesThe Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against … more ➔
Agri-biotechPairwise and Bayer collaborate to CRISPR short-stem maizeBayer and Pairwise extend their collaboration in precision breeding for five further years to develop CRISPR applications for Bayer’s Preceon Smart Corn System. more ➔
FinancingMystery solved: Mysthera Theapeutics launches with $3.5mMysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune … more ➔
financingMithra raises €20m through private placementWomen’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise €20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice … more ➔
